Clement Ngai

Wing Keung Clement Ngai

Baker & McKenzie LLP
Not admitted to practice law in this jurisdiction


Mr. Clement Ngai is a Partner of the Intellectual Property Group in the Shanghai office. He advises extensively on IP issues relating to technology research development in China; particularly for clients in the life science industries such as pharmaceutical, biotech, medical devices and other regulated sectors.  He regularly assists clients in market access, IP licensing, clinical trials, product registration and recalls, and technology transfers in China.

Clement is also a seasoned litigator who has handled many high profile IP litigations involving complicated technology. Having worked many years as an in-house legal counsel in US technology companies, Clement understands the internal needs of clients and gives practical advices.

Practice Focus

His practice focuses on pharmaceutical/regulatory issues and technology transactions in China. He is also experienced in handling IP litigation involving technology such as patent and trade secret cases.

Representative Legal Matters

  • Advising pharmaceutical and healthcare clients on issues relating to clinical trials, manufacturing, licensing, joint development projects, contract research, registration and renewal of pharmaceutical and medical device products in China
  • Representing major US chemical manufacturer and IT company in a patent litigation lawsuits in China
  • Representing US pharmaceutical client in trade secret infringement lawsuit (the case was subsequently selected as top 10 IP cases by Supreme People's Court in China
  • Advising French nutrition client on IP and technology issues in a divestment of China assets transaction
  • Advising US technology company in a MOU with a Chinese Provincial government to develop photovoltaic industry
  • Representing a European multinational industrial enzyme producer in the development of a second generation fuel ethanol technology project with a petrochemical firm in China
  • Advising multinational clients on IP protection strategies in China R&D centres
  • Advising a US Biotech equipment manufacturer on IP strategy for its R&D center in Shanghai
  • Advising a US Biotech company on joint development and pharmaceutical outsourcing issues in China
  • Advising on R&D IP matters and invention disclosures in China
  • Advising on IP strategy in relation to methanol-to-olefin technology in China

Professional Honors

  • Leading Individual (Healthcare and Life Sciences, China: Foreign Firms) – The Legal 500 (2020)
  • Leading Lawyer (Life Sciences (International Firms): China/Hong Kong) – Chambers Asia Pacific (2012-2021)
  • Patent Star (China) Managing Intellectual Property: IP Stars (2018-2019)
  • Recommended Litigation Lawyer (China: Foreign Firms) IAM Patent 1000 (2019)
  • Recommended Transactions Lawyer (China: Foreign Firms) IAM Patent 1000 (2018)
  • IP Star (China) Managing Intellectual Property (2015)
  • Finalist, 2006 China Law & Practice Award for China In-house Counsel

Professional Associations and Memberships

  • Chairman of Business Software Alliance, China Committee 2000-2006, Korea Committee 2000-2003 & India Committee 2004-2005
  • Regular speaker at many pharmaceutical and healthcare seminar and workshops


  • Hong Kong (1997)


  • The University of Hong Kong (P.C.LL.) (1994)
  • University of London (LL.B.) (1993)
  • Chinese University of Hong Kong (Master's Degree Philosophy) (1992)
  • The University of Hong Kong (B.Sc.) (1989)


  • Chinese
  • English
  • Mandarin